The 21-gene recurrence score assay (RS assay) (OncotypeDX; Genomic Health Inc, Redwood City, CA) quantifies risk of distant recurrence and overall survival in patients with node-negative, estrogen receptor (ER)-positive breast cancer [2]. Here, ESR1 is linked to breast cancer.